According to statistics compiled by Endpoints News, Goodwin has represented more clients in issuer-side biotechnology IPOs than any other law firm from January 1, 2020 through September 1, 2020.
Endpoints News referred to 2020 as a “booming year for biotech IPOs,” with 48 IPOs thus far raising approximately $11.375 billion dollars combined. That number already exceeds the 47 IPOs that took place throughout all of 2019.
These statistics further cement the positioning of Goodwin’s Life Sciences Capital Markets team as the go-to firm for IPOs and follow-on offerings in the biotechnology industry. The firm has advised on biotech IPOs with a total of over $5 billion in capital raised (January 1, 2020 – September 1, 2020), including both issuer and underwriter representation. On the issuer side, the firm has represented cutting-edge companies such as Kymera Therapeutics, Relay Therapeutics, Forma Therapeutics and Fusion Pharmaceuticals, while on the underwriter side, Goodwin was integral to the completion of Royalty Pharma’s $2.5 billion IPO, which is considered the largest IPO of 2020 YTD.Goodwin also has experience advising on SPAC IPOs and representing operating companies, their investors and SPACs in business combinations, or “deSPAC transactions,” across all key industries. This multidisciplinary team also structures the debt and equity financing transactions that are often needed to facilitate the closing of deSPAC transactions. Recently, the firm has structured innovative deSPAC transactions resulting in publicly traded companies such as Immatics NV, Open Lending Corporation and Cerevel Therapeutics Holdings, Inc. (announced), among others.